Company / Working Capital
Larimar Therapeutics, Inc. Working Capital History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$59.3M
FY2019
5-year range
$59.3M / $171.6M
FY2015-FY2019
Trend
-45.1%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has fluctuated over the past 6 years, ranging from $59M in FY2019 to $172M in FY2015.
Based on SEC 10-K filings.
$59M in FY2019 with a 5-year CAGR of -11.7%.
Declined from $98M to $59M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -21.2%
- 5-Year CAGR
- -11.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -11.7%, indicating a declining trend.
- In FY2019, working capital decreased 45.1% year-over-year.
- Peak working capital was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $59.3M | -45.1% |
| FY2018 | $108.0M | +10.6% |
| FY2017 | $97.6M | -19.3% |
| FY2016 | $121.0M | -29.5% |
| FY2015 | $171.6M | +55.6% |
| FY2014 | $110.3M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026